Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 100%Moderate 0 · 0%High 0 · 0%

Remdesivir and standard care vs placebo or usual care

Serious adverse events at up to day 28 · non‐hospitalised adults with mild COVID‐19

Remdesivir and standard care may leads to lower serious adverse events at up to day 28 compared with standard care (plus/minus placebo) (low certainty).

1 finding from 1 review

Remdesivir for the treatment of COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.27 [0.1, 0.7]
1 study · 562 participants
Low

Remdesivir and standard care vs placebo or usual care

Serious adverse events at up to day 28 · hospitalised individuals with COVID‐19 (moderate to severe disease)

Remdesivir and standard care showed no clear difference in serious adverse events at up to day 28 compared with standard care (plus/minus placebo) (low certainty).

1 finding from 1 review

Remdesivir for the treatment of COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.84 [0.65, 1.07]
4 studies · 2498 participants
Low